Optimi Health (OPTI.CN), up 2.5% on last look, on Tuesday said it completed a production run of its 5mg psilocybin finished drug product.
Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, The company also updated the product's bottling configuration to improve ease of use for prescribers and patients in the Australian market, a statement said.
Additional product from the same production run is earmarked to support upcoming clinical research in the United States and clinical trials in Europe across various indications, the company noted.
Optimi Health said all stages of manufacturing were completed in-house and on-site at its facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The company is also authorized by Health Canada to hold up to 20 kilograms of psilocybin and approximately 2,000 kilograms of biomass on site, giving it commercial-scale supply capacity.
Optimi Health shares were last seen up $0.20, to $8.10, on the Canadian Securities Exchange.
Price: $8.10, Change: $+0.20, Percent Change: +2.53%